Circassia Pharmaceuticals (GB:NIOX) has released an update.
Circassia Pharmaceuticals’ NIOX Group PLC reports a robust financial performance with a 12% revenue increase to £21.0m and an 11% growth in core Clinical business, leading to an impressive 14.5% rise in adjusted EBITDA at £7.1m. The company has also strengthened its balance sheet with net cash rising to £21.5m, reflecting strong cash inflow and prudent management despite a £4.2m dividend payout. Investors are anticipating further details in the upcoming half-year results on 24 September 2024.
For further insights into GB:NIOX stock, check out TipRanks’ Stock Analysis page.
